PTCT - PTC THERAPEUTICS, INC.

QQQ $ 615.11 $ -4.04 (-0.65 %)

DIA $ 470.25 $ 0.57 (0.12 %)

SPY $ 672.36 $ -0.79 (-0.12 %)

TLT $ 90.13 $ 0.15 (0.17 %)

GLD $ 362.19 $ -1.27 (-0.35 %)

Previous Close

$ 67.72

Open

$ 66.88

Bid

$ 68.85 x 6

Ask

$ 118.00 x 25

Day's Range

$ 66.22 - $ 68.80

52 Week Range

$ 35.95 - $ 69.88

Volume

1,341,005

Average Volume

Market Cap

5.44B

Beta (5Y Monthly)

$ 1.13

PE Ratio (TTM)

$ 7.23

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	11-04-2025	09-30-2025	10-Q
2	08-07-2025	06-30-2025	10-Q
3	05-06-2025	03-31-2025	10-Q
4	02-27-2025	12-31-2024	10-K
5	11-07-2024	09-30-2024	10-Q
6	08-08-2024	06-30-2024	10-Q
7	04-25-2024	03-31-2024	10-Q
8	02-29-2024	12-31-2023	10-K
9	10-26-2023	09-30-2023	10-Q
10	08-03-2023	06-30-2023	10-Q
11	04-27-2023	03-31-2023	10-Q
12	02-21-2023	12-31-2022	10-K
13	10-27-2022	09-30-2022	10-Q
14	08-04-2022	06-30-2022	10-Q
15	05-03-2022	03-31-2022	10-Q
16	02-22-2022	12-31-2021	10-K
17	10-28-2021	09-30-2021	10-Q
18	07-29-2021	06-30-2021	10-Q
19	05-04-2021	03-31-2021	10-Q
20	02-25-2021	12-31-2020	10-K
21	10-29-2020	09-30-2020	10-Q
22	08-05-2020	06-30-2020	10-Q
23	04-30-2020	03-31-2020	10-Q
24	03-02-2020	12-31-2019	10-K
25	10-30-2019	09-30-2019	10-Q
26	08-06-2019	06-30-2019	10-Q
27	05-02-2019	03-31-2019	10-Q
28	03-01-2019	12-31-2018	10-K
29	11-05-2018	09-30-2018	10-Q
30	08-07-2018	06-30-2018	10-Q
31	05-09-2018	03-31-2018	10-Q
32	03-06-2018	12-31-2017	10-K
33	11-02-2017	09-30-2017	10-Q
34	08-09-2017	06-30-2017	10-Q
35	05-08-2017	03-31-2017	10-Q
36	03-16-2017	12-31-2016	10-K
37	11-03-2016	09-30-2016	10-Q
38	08-04-2016	06-30-2016	10-Q
39	05-05-2016	03-31-2016	10-Q
40	02-29-2016	12-31-2015	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

PTC Therapeutics Raises FY2025 Sales Guida...
11/04/2025 21:03:05

PTC Therapeutics (NASDAQ:PTCT) raises FY2025 sales outlook from $650.000 million-$800.000 million to $750.000 million-$800.000 ...

PTC Therapeutics Q3 EPS $0.20 Beats $(1.42...
11/04/2025 21:02:41

PTC Therapeutics (NASDAQ:PTCT) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $(1....

Earnings Scheduled For November 4, 2025
11/04/2025 11:12:08

Jefferies Maintains Buy on PTC Therapeutic...
10/28/2025 18:54:28

Jefferies analyst Kelly Shi maintains PTC Therapeutics (NASDAQ:PTCT) with a Buy and raises the price target from $63 to $77.

PTC Therapeutics Could Challenge BioMarin ...
09/08/2025 17:56:24

BioMarin's Palynziq significantly lowered blood phenylalanine in teens with PKU, with nearly half reaching target levels in...

Cantor Fitzgerald Reiterates Overweight on...
09/03/2025 13:49:29

Cantor Fitzgerald analyst Kristen Kluska reiterates PTC Therapeutics (NASDAQ:PTCT) with a Overweight and maintains $118 pric...

ptc-therapeutics-stock-is-stuck-in-a-multi-year-slump

PTC Therapeutics Stock Is Stuck In A Multi...
08/21/2025 14:00:45

PTC Therapeutics is stuck with uncertainty stretching through 2030. Here's why the stock remains a long-term avoid.

Wells Fargo Maintains Overweight on PTC Th...
08/20/2025 18:42:36

Wells Fargo analyst Tiago Fauth maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and lowers the price target from ...

Morgan Stanley Maintains Overweight on PTC...
08/20/2025 15:53:58

Morgan Stanley analyst Jeffrey Hung maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and lowers the price target f...

B of A Securities Maintains Buy on PTC The...
08/20/2025 12:21:22

B of A Securities analyst Tazeen Ahmad maintains PTC Therapeutics (NASDAQ:PTCT) with a Buy and lowers the price target from ...

ptc-therapeutics-faces-fda-rejection-on-rare-disease-treatment-over-efficacy-concerns

PTC Therapeutics Faces FDA Rejection On Ra...
08/19/2025 15:20:22

FDA rejected PTC Therapeutics' vatiquinone for Friedreich's ataxia, citing insufficient efficacy data and requiring ano...

Trading Halt: Halt status updated at 8:25:...
08/19/2025 12:25:16

PTC Therapeutics Receives Complete Respons...
08/19/2025 12:03:56

Trading Halt: Halted at 7:55:00 a.m. ET - ...
08/19/2025 11:55:04

RBC Capital Maintains Outperform on PTC Th...
08/08/2025 18:29:10

RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Outperform and raises the price target fr...

Wells Fargo Maintains Overweight on PTC Th...
08/08/2025 15:26:13

Wells Fargo analyst Tiago Fauth maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from ...

PTC Therapeutics Affirms FY2025 Sales Guid...
08/07/2025 20:02:35

PTC Therapeutics (NASDAQ:PTCT) affirms FY2025 sales outlook from $650.00 million-$800.00 million to $650.00 million-$800.00 mil...

PTC Therapeutics Q2 EPS $(0.83) Beats $(0....
08/07/2025 20:02:05

PTC Therapeutics (NASDAQ:PTCT) reported quarterly losses of $(0.83) per share which beat the analyst consensus estimate of $(0....

Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

PTC Therapeutics Earnings Preview
08/06/2025 17:02:22